Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

Nurix establishes new subsidiary
September 2020
SHARING OPTIONS:

SAN FRANCISCO—Nurix Therapeutics Inc. recently formed DeCART Therapeutics as a wholly owned subsidiary, one that will focus on adoptive cell therapy. The new firm will unite Nurix’s proprietary targeted protein modulation drugs and T cell genetic engineering technologies in pursuit of developing a drug-enhanced chimeric antigen receptor T cell process for treating cancer. Nurix founded the company in partnership with Dr. Carl June, the Richard W. Vague Professor in Immunotherapy and director of the Center for Cellular Immunotherapies in the Abramson Cancer Center of the University of Pennsylvania, who will lead the founding team and hold the position of chairman on DeCART’s scientific advisory board.
 
Dr. Arthur T. Sands, CEO of Nurix, commented in part that “Together with DeCART, we plan to introduce a new generation of drug-enhanced CAR T products for patients by integrating pharmacologic control of protein levels within T cells.”

Back



PAGE UTILITIES


CONTACT US
DDNEWS
1000 N West Street, Suite 1200,
Wilmington, Delaware, 19801
Ph: 888-781-0328 |  Fax: 705-528-0270
 
© Copyright 2020 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.